arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CERUS CORP

CERS
$2.13 ▼ -0.28 (-11.62%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CERUS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $406.0M
Dividend Yield —
Revenue Growth 16.1% ↗
Op. Margin -3.7% ↗
ROIC -13.8% ↗
FCF / Share $0.01 ↘
Trailing P/E —
Price / Book 6.4x
FCF Yield 0.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$233.80M
↑ +16.1% —
Net Income Profit after all expenses
$-15.63M
↑ +25.3% —
Operating Margin Operating profit as % of sales
-3.7%
↑ +47.5% 21th
FCF / Share Free cash flow per share
$0.01
↓ -87.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
22
Returns ↑
26
Financial Health ↑
45
Cash Quality
19

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters